Raltegravir and Ramipril drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Raltegravir (raltegravir) and Ramipril (ramipril). Common drug interactions include pathogen resistance among females and brain stem stroke among males.

The phase IV clinical study analyzes what interactions people have when they take Raltegravir and Ramipril. It is created by eHealthMe based on reports of 75 people who take the same drugs from the FDA, and is updated regularly.

What is Raltegravir?

Raltegravir has active ingredients of raltegravir. eHealthMe is studying from 5,054 Raltegravir users. Check the latest studies of Raltegravir.

What is Ramipril?

Ramipril has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 147,397 Ramipril users. Check the latest studies of Ramipril.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 29, 2026

75 people who take Raltegravir and Ramipril together, and have interactions are studied.

Raltegravir and Ramipril drug interactions.

What are the common drug interactions of Raltegravir and Ramipril, by gender? *:

female:

  1. Pathogen resistance
  2. Drug resistance (reduction in effectiveness of a drug)
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  4. Diarrhoea
  5. Migraine (headache)
  6. Upper respiratory tract infection
  7. Compulsive sexual behaviour (unable to manage his/her sexual behaviour)
  8. Compulsive shopping
  9. Drug ineffective
  10. Injury

male:

  1. Brain stem stroke (rapid loss of brain function due to disturbance in the blood supply to the brain)
  2. Fall
  3. Cardiac arrest
  4. Blood creatinine increased
  5. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  6. Foetal exposure during pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect)
  7. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  8. Neutropenia (an abnormally low number of neutrophils)
  9. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  10. Platelet count decreased

What are the common drug interactions of Raltegravir and Ramipril, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Pathogen resistance
  2. Drug resistance (reduction in effectiveness of a drug)
  3. Drug ineffective
  4. Nephropathy toxic (damage to kidney due to toxins)
  5. Renal failure (kidney dysfunction)
  6. Renal impairment (severely reduced kidney function)
  7. Secondary hypertension (elevated blood pressure that results from an underlying, identifiable, often correctable cause)

30-39:

n/a

40-49:

  1. Drug ineffective
  2. Drug resistance (reduction in effectiveness of a drug)
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  4. Diarrhoea
  5. Migraine (headache)
  6. Upper respiratory tract infection
  7. Cardiac arrest
  8. Angina pectoris (chest pain due to ischemia of the heart muscle)
  9. Arthralgia (joint pain)
  10. Cerebral infarction (less blood supply to brain resulting tissue damage)

50-59:

  1. Device related infection
  2. Epistaxis (bleed from the nose)
  3. Lymphangitis (inflammation of the lymph channel)
  4. Post procedural complication
  5. Blood creatinine increased
  6. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  7. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  8. Neutropenia (an abnormally low number of neutrophils)
  9. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  10. Platelet count decreased

60+:

  1. Anaemia (lack of blood)
  2. General physical health deterioration (weak health status)
  3. Malignant neoplasm progression (cancer tumour came back)
  4. Nausea (feeling of having an urge to vomit)
  5. Osteoporotic fracture (fracture due to weak bone)
  6. Pain
  7. Rash

What are the existing conditions these people have? *

  1. Hiv Infection: 38 people, 50.67%
  2. Hepatitis B: 11 people, 14.67%
  3. High Blood Cholesterol: 6 people, 8.00%
  4. Asthma: 5 people, 6.67%
  5. Depression: 4 people, 5.33%

* Approximation only. Some reports may have incomplete information.

Do you take Raltegravir and Ramipril?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Raltegravir and Ramipril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Raltegravir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ramipril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Raltegravir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ramipril and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on raltegravir and ramipril (the active ingredients of Raltegravir and Ramipril, respectively), and Raltegravir and Ramipril (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: